Synthetic Drugs

March 18, 2024 | Fact Sheets, Novel Psychoactive Substances, Opioids, Public Safety, Stimulants, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) is monitoring the emergence of novel psychoactive substances (NPS) appearing on the streets of the United States. This fact sheet, which focuses on Xylazine, was originally the second in a series that highlights these dangerous drugs. This is an update to the original version....

January 19, 2024 | Controlled Substances, Fentanyl, Harm Reduction, Law Enforcement, Legal & Legislative Research, Opioids, Public Health, Public Safety, Sharps/Syringes, Substance Misuse, Synthetic Drugs

Given the increased emphasis in recent years on using harm reduction strategies to slow the overdose crisis, the hurdle posed by state drug paraphernalia laws to freely allowing drug checking services or establishing syringe services programs is not inconspicuous. Accordingly, in 2022, LAPPA first undertook an extensive research project to determine how drug paraphernalia laws throughout the 50 states, District of Columbia, and all U.S. territories treat drug checking equipment (including fentanyl test strips and other items) and needles/syringes. This January 2024 version, which sets forth a summary of state and territory laws as of December 2023, is an update to the original report. ...

December 11, 2023 | Controlled Substances, Legal & Legislative Research, Opioids, Prescription Drugs, Substance Misuse, Synthetic Drugs

In this survey, the Legislative Analysis and Public Policy Association (LAPPA) examines the policy response at the state level to the spread of pill presses used to create counterfeit drugs. There is relatively little policy in this area compared to federal law, and most innovation is relatively recent.  Findings are presented jurisdiction by jurisdiction for easy comparison among states and between current state- and federal law....

October 31, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) continues to monitor the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a brand new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, the sixth in a series highlighting these dangerous drugs, is an examination of bromazolam....

September 18, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) continues to monitor the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a brand new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, the fifth in a series highlighting these dangerous drugs, is an examination of nitazenes....

September 14, 2023 | Controlled Substances, Fentanyl, Legal & Legislative Research, Public Health, Public Safety, Substance Misuse, Synthetic Drugs

In this survey, the Legislative Analysis and Public Policy Association (LAPPA) examines the legislative and regulatory response at the state level to the issue of fentanyl cleanup. As at the federal level, there is little policy in this area, and the only exceptions to that rule are very recent. Findings are presented jurisdiction by jurisdiction for easy comparison among the states....

June 6, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) is monitoring the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, the fourth in a series highlighting these potentially dangerous drugs, examines isotonitazene, a synthetic opioid recently classified as a Schedule I controlled substance under the federal Controlled Substances Act....